STAB - Statera Biopharma, Inc. Stock Price, Fair Value and News

0USD0Delayed as of 17 May 2024, 10:01 am ET

STAB Stock Price

View Fullscreen

STAB RSI Chart

STAB Valuation

STAB Price/Sales (Trailing)

STAB Profitability

STAB Fundamentals

STAB Revenue

STAB Earnings

Breaking Down STAB Revenue

Trailing 12 Months

-100%

How does STAB drawdown profile look like?

STAB Financial Health

STAB Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	2.5M	3.3M	3.7M	0
2021	0	0	343.4K	1.5M
2020	1.1M	857.8K	631.8K	262.9K
2019	1.1M	993.9K	980.2K	1.1M
2018	1.6M	1.8M	1.8M	1.1M
2017	3.3M	2.9M	2.1M	1.9M
2016	2.9M	3.2M	3.8M	3.5M
2015	3.0M	2.7M	2.8M	2.7M
2014	8.5M	7.4M	6.2M	3.7M
2013	4.0M	5.4M	6.8M	8.5M
2012	7.2M	6.9M	3.4M	3.6M
2011	13.6M	10.0M	10.6M	8.8M
2010	0	14.7M	15.0M	15.3M
2009	0	0	0	14.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Statera Biopharma, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 28, 2021	markvicka taunia	acquired	-	-	100,000	chief operating officer
Sep 09, 2021	barbarick steve k	acquired	-	-	60,000	-
Sep 09, 2021	saluck randy s.	acquired	-	-	60,000	-
Sep 09, 2021	verny lea	acquired	-	-	60,000	-

Which funds bought or sold STAB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Mar 04, 2024	TUCKER ASSET MANAGEMENT LLC	unchanged	-	1.00	1.00	-%
Nov 21, 2022	FourThought Financial, LLC	unchanged	-	-	-	-%
Nov 03, 2022	DOWLING & YAHNKE LLC	unchanged	-	-4,000	4,000	-%

Are Funds Buying or Selling STAB?

Are funds buying STAB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own STAB

No. of Funds

Unveiling Statera Biopharma, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 15, 2022	harpel james w	3.51%	1,126,956	SC 13G/A

Statera Biopharma, Inc. News

Latest updates

Statera Biopharma, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1
Revenue	-12.8%	670	769	998	1,251	237	-	44.00	63.00	156	369	270	277	198	236	283	392	228	870	297	206	575
Gross Profit	-11.8%	501	568	644	878	121	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-40.2%	2,048	3,421	7,258	78,060	9,765	3,391	6,171	655	600	650	788	1,049	988	864	1,551	1,460	2,064	2,084	1,494	1,777	2,194
S&GA Expenses	-31.1%	13.00	19.00	37.00	53.00	23.00	-431	-	485	382	369	526	449	475	329	712	551	727	560	575	588	777
R&D Expenses	-76.3%	231	974	3,242	5,555	3,435	623	4,383	170	218	281	262	600	513	534	839	909	1,336	1,524	919	1,188	1,417
Interest Expenses	-	-	-	540	972	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	4.1%	-3,348	-3,490	-7,759	-77,245	-12,719	-4,836	-5,678	-369	-601	-688	-449	-633	-893	-404	-1,104	-872	-1,258	-1,305	-1,260	-5,612	-1,663
Net Income Margin	19.9%	-24.91*	-31.11*	-44.01*	-68.49*	-24.92*	-43.69*	-11.62*	-2.46*	-2.22*	-2.39*	-2.43*	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-375.7%	-801	-168	-3,768	-7,456	-15,283	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3
Assets	-5.9%	12,749	13,542	13,510	21,170	98,036	13,829	14,700	1,035	3,231	4,079	1,865	2,037	2,229	3,086	3,780	4,534	5,698	7,056	8,370	9,629	10,872
Current Assets	-27.3%	1,214	1,669	1,438	4,147	13,328	13,824	14,694	926	3,225	4,070	1,833	2,003	2,193	3,047	3,725	4,476	5,639	6,995	8,308	9,580	10,822
Cash Equivalents	-8.6%	506	554	152	1,845	9,216	13,777	14,359	594	2,721	3,409	1,059	1,126	1,487	2,238	2,799	3,617	4,379	4,007	4,586	4,231	4,591
Net PPE	-42.3%	106	184	202	202	119	5.00	6.00	9.00	6.00	9.00	12.00	16.00	17.00	20.00	24.00	28.00	25.00	28.00	32.00	19.00	18.00
Goodwill	0%	9,267	9,267	9,267	9,267	76,973	12,634	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	12.0%	22,917	20,464	15,945	22,676	23,841	17,458	11,075	4,691	484	787	1,085	1,053	566	943	1,018	920	1,602	1,797	2,156	2,221	2,272
Current Liabilities	13.0%	22,231	19,670	15,073	11,245	10,187	-	-	4,621	484	787	1,085	1,053	566	940	1,011	912	1,593	1,797	2,156	2,213	2,272
Shareholder's Equity	-	-	-	-	-	74,208	144,331	150,923	143,486	147,754	3,292	779	984	247	2,142	2,761	3,614	4,096	5,260	6,213	7,408	3,364
Retained Earnings	-2.4%	-144,075	-140,700	-137,200	-129,482	-52,300	-170,301	-169,642	-27,762	-168,409	-167,663	-167,294	-166,705	-165,998	-165,548	-164,931	-164,058	-163,626	-162,522	-161,671	-160,446	-159,277
Additional Paid-In Capital	0.0%	133,527	133,465	134,529	127,743	126,220	179,476	179,475	23,947	166,765	166,503	163,666	163,162	163,162	163,162	163,162	163,162	163,162	163,162	163,162	163,106	163,106
Shares Outstanding	2.2%	50,745	49,641	49,980	35,484	27,037	24,527	24,424	13,376	3,081	11,652	11,353	11,298	11,298	-	-	-	-	-	-	-	-
Minority Interest	8.3%	73.00	67.00	50.00	61.00	72.00	4,959	4,962	-	4,972	5,000	4,993	5,040	5,026	5,048	5,060	5,066	5,094	5,129	5,177	5,209	5,235
Float	-	-	-	-	-	-	48,863	-	-	-	33,225	-	-	-	16,382	-	-	-	11,634	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3
Cashflow From Operations	-375.7%	-801	-168	-3,761	-7,359	-15,219	-3,021	-2,592	3,281	-7,461	-476	-425	-364	-713	-758	-827	-1,172	-1,159	-1,082	-1,199	-1,279	-1,432
Share Based Compensation	73.0%	-287	-1,065	453	1,102	1,179	1,963	1,816	2,826	-	-	-	-	-	-	-	-	-	-	-	-	-
Cashflow From Investing	-	-	-	-6.45	-96.91	13,045	520	-4.68	-3.02	-49.86	-	-	-1.76	-31.74	190	-	406	1,548	512	1,501	920	2,094
Cashflow From Financing	42.3%	712	500	-2,898	89.00	672	18,072	2,155	-3,004	5,522	2,783	382	-	-	-	-	-	-	-	55.00	-	-
Buy Backs	-	-	-	51.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

STAB Income Statement

2022-09-30

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues:
Grants and contracts	$ 670,473	$ 236,519	$ 2,437,139	$ 236,519
Cost of goods sold	169,354	115,927	723,961	115,927
Gross profit	501,119	120,592	1,713,178	120,592
Operating expenses:
Research and development	230,604	3,434,977	4,446,535	6,274,936
Sales and marketing expense	13,350	23,242	69,750	26,037
General and administrative	1,803,607	6,306,323	8,210,391	14,981,086
Total operating expenses	2,047,561	9,764,542	12,726,676	21,282,059
Loss from operations	(1,546,442)	(9,643,950)	(11,013,498)	(21,161,467)
Other expense:
Interest and other expense	(1,810,473)	(3,089,301)	(3,593,897)	(3,463,572)
Total other expense	(1,810,473)	(3,089,301)	(3,593,897)	(3,463,572)
Income from discontinued operations, net of income taxes	0	(1)	0	(1)
Net loss	(3,356,915)	(12,733,250)	(14,607,395)	(24,625,038)
Net loss attributable to noncontrolling interests	8,103	13,419	13,979	13,419
Net loss attributable to Statera Biopharma, Inc.	$ (3,348,812)	$ (12,719,831)	$ (14,593,416)	$ (24,611,619)
Net loss attributable to common stockholders per share of common stock, basic and diluted (in dollars per share)	$ (0.07)	$ (0.47)	$ (0.32)	$ (0.86)
Weighted average number of shares used in calculating net loss per share, basic and diluted (in shares)	50,234,111	27,036,583	45,906,659	28,671,422

STAB Balance Sheet

2022-09-30

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 506,098	$ 1,844,732
Short-term investments	0	134,603
Accounts receivable	183,383	216,183
Prepaid expenses	97,515	981,895
Contract asset	178,048	132,572
Other current assets	248,457	837,358
Total current assets	1,213,501	4,147,343
Non-current assets:
Operating lease right-of-use assets	914,226	964,331
Restricted cash	0	5,000,000
Goodwill	9,267,007	9,267,007
Intangible assets, net	1,239,853	1,580,980
Property and equipment, net	106,415	201,901
Total non-current assets	11,527,501	17,014,219
Assets of discontinued operation	8,123	8,123
Total assets	12,749,125	21,169,685
Current liabilities:
Accounts payable and accrued expenses	14,442,069	5,715,956
Current portion of operating lease liabilities	323,631	254,998
Deferred revenue	386,929	373,468
Stock issuances due	682,078	325,828
Notes payable	6,396,486	4,575,000
Total current liabilities	22,231,193	11,245,250
Operating lease liabilities, net of current portion	686,140	806,140
Long-term debt	0	10,625,000
Total long-term liabilities	686,140	11,431,140
Liabilities of discontinued operation	63	63
Total liabilities	22,917,396	22,676,453
Stockholders’ equity (deficit):
Preferred stock, $.005 par value; 1,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 0 shares issued and outstanding as of September 30, 2022 and December 31, 2021	0	0
Common stock, $.005 par value; 150,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 50,744,653 shares issued and outstanding as of September 30, 2022 and 35,484,106 shares issued and outstanding as of December 31, 2021	253,724	177,421
Additional paid-in capital	133,526,843	127,743,333
Accumulated other comprehensive income (loss)	53,695	(6,651)
Accumulated deficit	(144,075,557)	(129,482,141)
Total Statera Biopharma, Inc. stockholders’ deficit	(10,241,295)	(1,568,038)
Noncontrolling interest in stockholders’ equity	73,024	61,270
Total stockholders’ deficit	(10,168,271)	(1,506,768)
Total liabilities and stockholders’ deficit	$ 12,749,125	$ 21,169,685

About Statera Biopharma, Inc.

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado.

CEO	Mr. Michael Kevin Handley
WEBSITE	staterabiopharma.com
INDUSTRY	Biotechnology
EMPLOYEES	46

Statera Biopharma, Inc. Frequently Asked Questions

What is the ticker symbol for Statera Biopharma, Inc.? What does STAB stand for in stocks?

STAB is the stock ticker symbol of Statera Biopharma, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Statera Biopharma, Inc. (STAB)?

As of Thu May 16 2024, market cap of Statera Biopharma, Inc. is 0. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of STAB stock?

You can check STAB's fair value in chart for subscribers.

What is the fair value of STAB stock?

You can check STAB's fair value in chart for subscribers. The fair value of Statera Biopharma, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Statera Biopharma, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for STAB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Statera Biopharma, Inc. a good stock to buy?

The fair value guage provides a quick view whether STAB is over valued or under valued. Whether Statera Biopharma, Inc. is cheap or expensive depends on the assumptions which impact Statera Biopharma, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for STAB.

What is Statera Biopharma, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, STAB's PE ratio (Price to Earnings) is 0 and Price to Sales (PS) ratio is 0. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. STAB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Statera Biopharma, Inc.'s stock?

In the past 10 years, Statera Biopharma, Inc. has provided -1 (multiply by 100 for percentage) rate of return.